Romosozumab leads to a greater increase in bone mineral density (BMD) than teriparatide in postmenopausal women, with lower discontinuation rates and fewer cardiovascular events. Romosozumab and ...

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial. The findings were ...

In postmenopausal women with osteoporosis, prior fracture, and type 2 diabetes, 12 months of romosozumab significantly improved bone strength when combined with alendronate, compared with alendronate ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

SEATTLE -- The monoclonal antibody romosozumab (Evenity) increased bone mineral density (BMD) in premenopausal women with idiopathic osteoporosis, according to a small, phase II open-label study.

Romosozumab is a US Food and Drug Administration-approved humanized monoclonal antibody used to treat osteoporosis in postmenopausal women with a high risk for fracture. The study included 70 adults ...